Arranca en Valencia el Congreso de la EAACI
May 31, 2024 13:11 ET
|
European Academy of Allergy and Clinical Immunology
VALENCIA, España, May 31, 2024 (GLOBE NEWSWIRE) -- Con el lema “Revolucionando la atención al paciente a través del poder de la ciencia de los datos”, ha comenzado el congreso internacional...
EAACI Congress Kicks Off in Valencia, Spain
May 31, 2024 13:11 ET
|
European Academy of Allergy and Clinical Immunology
EAACI Congress Kicks Off in Valencia, Spain
Precision Medicine, Immunotherapy, and Artificial Intelligence (AI) as Key Topics
Allergy Vaccine Market Trends, Forecast and Competitive Analysis: A $3.6 Billion Market by 2030 with a CAGR of 7.5% from 2024 to 2030
May 31, 2024 04:18 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Allergy Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...
Presentación del Congreso de la Academia Europea de Alergología e Inmunología Clínica (EAACI) que se celebrará en Valencia del 31 de mayo al 3 de junio
May 30, 2024 09:37 ET
|
European Academy of Allergy and Clinical Immunology
VALENCIA, España, May 30, 2024 (GLOBE NEWSWIRE) -- Con el lema «Revolucionando la atención al paciente a través del poder de la ciencia de los datos», el congreso destacará el papel...
Presentation of the Congress of the European Academy of Allergy and Clinical Immunology (EAACI) to be held in Valencia from May 31 to June 3
May 30, 2024 09:37 ET
|
European Academy of Allergy and Clinical Immunology
We are delighted to invite you to the opening press conference of our EAACI Annual Congress 2024 in Valencia or online via the link below.
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
May 23, 2024 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and...
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
May 07, 2024 04:09 ET
|
AKAMPION
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...
欧州アレルギー・臨床免疫学会2024 (EAACI Congress 2024)：アレルギー治療の革新と進歩
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
学会中は、環境科学の進歩、食物アレルギー、免疫療法の革新、小児アレルギーなどに焦点を当てた、150を超える科学セッションが開催される。精密医療、AI、免疫療法、免疫調節剤が、最大規模のアレルギーおよび免疫学学会に集結。同学会は、5月31日から6月3日までスペインのバレンシアで開催される。 スペイン、バレンシア発, April 30, 2024 (GLOBE NEWSWIRE) --...
Kongres EAACI 2024: Inovasi dan Kemajuan dalam Pengobatan Alergi
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Lebih dari 150 sesi ilmiah akan dipresentasikan selama pelaksanaan kongres, dengan fokus di berbagai bidang yang di antaranya mencakup kemajuan dalam sains lingkungan, alergi makanan, inovasi...
Congrès EAACI 2024 : innovations et progrès dans le traitement des allergies
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Lors de ce congrès, plus de 150 sessions scientifiques seront présentées. Les sujets abordés se concentreront sur les progrès de la science environnementale, les allergies alimentaires, les...